Form 4: Immuneering Corp CEO Benjamin J. Zeskind Acquires 480,000 Stock Options

Immuneering Corp's CEO, Benjamin J. Zeskind, reports the acquisition of 480,000 stock options with an exercise price of $1.91, vesting monthly over four years.

Summary

• Benjamin J. Zeskind, the President and CEO of Immuneering Corp, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 5, 2025.
• Zeskind acquired 480,000 stock options with an exercise price of $1.91.
• The options vest in equal monthly installments over a four-year period, commencing on February 1, 2025, and will be fully vested by January 1, 2029.
• The expiration date for these options is February 5, 2035.
• Following the reported transaction, Zeskind directly owns 480,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard executive compensation practice. The acquisition of stock options can be seen as a positive sign, aligning management's interests with shareholders, but it's a routine event.

Positives

• The acquisition of stock options by the CEO could align his interests with those of the shareholders, potentially driving company performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the equity-based compensation of key executives.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with the company's performance.

Key Dates